We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Shuwen Biotech‘s PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs
Product News

Shuwen Biotech‘s PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs

Shuwen Biotech‘s PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs
Product News

Shuwen Biotech‘s PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs

Credit: Shuwen Biotech

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Shuwen Biotech‘s PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Shuwen Biotech is the first in China to launch a locally manufactured proprietary PD-L1 test kit, which can accurately determine the expression status of PD-L1 in tumor tissues, and to provide laboratory testing services for anti-PD-L1/PD-1 drug development.

Recently, the investigation of the safety, efficacy and molecular marker efficacy of Hengrui Medicince’s anti-PD-1 drug, SHR1210, in the treatment of patients with advanced esophageal squamous cell carcinoma who failed conventional therapy was published in the March 2018 issue of Clinical Cancer Research, in which one of Shuwen Biotech’s PD-L1 detection kits was used and clinical results showed that patients positive for PD-L1 (PD-L1 expression ≥ 5%) have a higher objective response rate.

Shuwen Biotech’s PD-L1 kits and testing services have been used by leading pharmaceutical companies for dozens of clinical trials against PD-1 immunotherapeutics, contributing to the development of tumor immunotherapy drugs. Shuwen Biotech's CAP-certified Shuwen Guanz Diagnostic Laboratories also successfully passed CAP’s multi-site, multi-country proficiency testing for PD-L1 testing.
Advertisement